CSL Limited's Transformation Program targets $500–$550M in annual pre-tax cost reductions by FY28. Read why CSLLY stock is a ...
New $1.5 billion investment builds on over $3 billion already spent on CSL's U.S. operations since 2018 Expansion will create at least 300 new jobs and enhance production of plasma-derived therapies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results